Get the Stockscreener App
1.00
3.09%
0.03
After Hours:
1.04
0.04
+4.00%
Regulus Therapeutics Inc stock is traded at $1.00, with a volume of 1.26M.
It is up +3.09% in the last 24 hours and down -33.33% over the past month.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$0.97
Open:
$0.975
24h Volume:
1.26M
Relative Volume:
2.96
Market Cap:
$65.50M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-0.6329
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
-17.36%
1M Performance:
-33.33%
6M Performance:
-45.95%
1Y Performance:
-19.35%
1-Day Range:
$0.9662
$1.1548
1-Week Range:
$0.8301
$1.29
52-Week Range:
$0.8301
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Name
Regulus Therapeutics Inc
Sector
Industry
Phone
858-202-6300
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Compare RGLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.00 | 65.50M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Mar-18-24 | Initiated | Leerink Partners | Outperform |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Jan-05-18 | Initiated | Leerink Partners | Outperform |
| Jun-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Mar-06-17 | Reiterated | Wedbush | Outperform |
| Jan-30-17 | Downgrade | Needham | Buy → Hold |
| Jan-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Dec-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Nov-02-16 | Reiterated | Needham | Buy |
| Jul-25-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | FBR Capital | Outperform |
| Jun-28-16 | Reiterated | Needham | Buy |
| Jun-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Apr-13-16 | Initiated | Chardan Capital Markets | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Apr-21-15 | Resumed | FBR Capital | Outperform |
| Nov-24-14 | Initiated | Deutsche Bank | Buy |
| Aug-07-14 | Reiterated | FBR Capital | Outperform |
| Aug-14-13 | Reiterated | Needham | Buy |
View All
Regulus Therapeutics Inc Stock (RGLS) Latest News
Regulus stock tumbles 24% amid study, regulatory updates - MSN
Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data - Yahoo Finance
Regulus Therapeutics Kidney Disease Treatment Shows Response in Early-stage Trial -- Shares Fall - Marketscreener.com
Regulus stock tumbles 24% amid study, regulatory updates (RGLS:NASDAQ) - Seeking Alpha
Regulus reports progress in ADPKD trial and FDA talks - MSN
Regulus Therapeutics (RGLS) Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen - StreetInsider.com
Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - StockTitan
Regulus Therapeutics stock hits 52-week low at $1.16 - MSN
Barclays PLC Grows Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics CFO sells shares worth $55,333 By Investing.com - Investing.com South Africa
Jane Street Group LLC Takes $46,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics president sells $39,721 in stock By Investing.com - Investing.com Australia
Regulus Therapeutics CEO sells shares worth $160,494 By Investing.com - Investing.com Canada
Regulus therapeutics executive sells shares worth $55,119 By Investing.com - Investing.com Nigeria
Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of Stock - MarketBeat
Joseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock - MarketBeat
Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada Sells 38,716 Shares - MarketBeat
Regulus therapeutics executive sells shares worth $55,119 - Investing.com India
Regulus Therapeutics president sells $39,721 in stock - Investing.com
Regulus Therapeutics CFO sells shares worth $55,333 - Investing.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Consensus PT from Analysts - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by State Street Corp - Defense World
This Biotech Wasted No Time Stealing The Premarket Show - MSN
Regulus Therapeutics Announces Completion of Enrollment in Secon - GuruFocus.com
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts - Defense World
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
Fmr LLC Reduces Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus To Provide First Quarter 2017 Financial Results On May 4, 2017 - BioSpace
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages - MarketBeat
The Manufacturers Life Insurance Company Purchases New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - StockTitan
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - Longview News-Journal
Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance
RA Capital Management L.P. Sells 5,483,166 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
NEA Management Company LLC Buys Shares of 6,467,802 Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces Participation at Upcoming Healthc - GuruFocus.com
Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80 - MarketBeat
Regulus Therapeutics Reports Q3 2024 Financial Results - TipRanks
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - GuruFocus.com
Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World
RA Capital Management's Strategic Reduction in Regulus Therapeutics Holdings - GuruFocus.com
Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com
Regulus Therapeutics Inc Stock (RGLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):